CHRNB2

Chr 1AD

cholinergic receptor nicotinic beta 2 subunit

Also known as: EFNL3, nAChRB2

Neuronal acetylcholine receptors are homo- or heteropentameric complexes composed of homologous alpha and beta subunits. They belong to a superfamily of ligand-gated ion channels which allow the flow of sodium and potassium across the plasma membrane in response to ligands such as acetylcholine and nicotine. This gene encodes one of several beta subunits. Mutations in this gene are associated with autosomal dominant nocturnal frontal lobe epilepsy. [provided by RefSeq, Jul 2008]

GeneReviewsOMIMResearchGenerating clinical summary…
GOFmechanismADLOEUF 0.821 OMIM phenotype
Clinical SummaryCHRNB2
🧬
Gene-Disease Validity (ClinGen)
familial sleep-related hypermotor epilepsy · ADDefinitive

Definitive — sufficient evidence for diagnostic panels

Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
7 unique Pathogenic / Likely Pathogenic· 378 VUS of 694 total submissions
📖
GeneReview available — CHRNB2
Authoritative clinical overview · Recommended first read
Open GeneReview ↗

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint?
0.82LOEUF
pLI 0.001
Z-score 2.11
OE 0.46 (0.270.82)
Tolerant

Typical tolerance to LoF variation

Missense Constraint?
2.10Z-score
OE missense 0.67 (0.600.75)
221 obs / 328.2 exp
Mild constraint

Moderately missense-constrained (top ~2.5%)

Observed / Expected Ratios?
LoF OE?0.46 (0.270.82)
00.351.4
Missense OE?0.67 (0.600.75)
00.61.4
Synonymous OE?1.02
01.21.6
LoF obs/exp: 8 / 17.6Missense obs/exp: 221 / 328.2Syn Z: -0.20
Curated Mechanism (G2P)Gene2Phenotype (DDG2P) ↗
strongCHRNB2-related nocturnal frontal lobe epilepsyGOFAD

This gene — mechanism propensity

DN
0.82top 10%
GOF
0.85top 5%
LOF
0.1993th %ile

This gene has evidence for multiple mechanisms of pathogenicity (gain-of-function and dominant-negative). Both the Badonyi & Marsh prediction and the broader genomic evidence point to gain-of-function as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

GOFprediction above median
DNprediction above median

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

ClinVar Variant Classifications

694 submitted variants in ClinVar

Classification Summary

Pathogenic2
Likely Pathogenic5
VUS378
Likely Benign260
Benign18
Conflicting29
2
Pathogenic
5
Likely Pathogenic
378
VUS
260
Likely Benign
18
Benign
29
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
2
0
0
2
Likely Pathogenic
1
4
0
0
5
VUS
42
321
7
8
378
Likely Benign
0
14
51
195
260
Benign
0
0
17
1
18
Conflicting
29
Total4334175204692

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

17 pathogenic / likely-pathogenic (of 23) ClinVar copy-number / structural variants overlap CHRNB2 — these span large chromosomal regions, not the gene specifically, and are excluded from the counts above. Explore in CNV tools →

Protein Context — Lollipop Plot

CHRNB2 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →